{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"37","value":"20"}]}],"title":"Grades II to IV acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"22","value":"8"}]}],"title":"Grades III to IV acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"33","value":"16"}]}],"title":"Moderate chronic GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"27","value":"12"}]}],"title":"Severe chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The number of participants that developed graft-versus-host-disease before or at 100 days after transplant","dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine, Melphalan \\& Post-transplant cyclophosphamide\n\nFludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;\n\nMelphalan\n\nCyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.\n\nperipheral blood stem cell transplant","id":"OG000","title":"Reduced-Intensity Mismatched Transplant"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days","title":"GVHD Incidence","type":"SECONDARY","unitOfMeasure":"percentage of patients"}